Loading...
OTCM
CSLLY
Market cap59bUSD
Dec 04, Last price  
61.53USD
1D
1.79%
1Q
-9.98%
Jan 2017
69.64%
Name

CSL Ltd

Chart & Performance

D1W1MN
OTCM:CSLLY chart
P/E
9.92
P/S
1.93
EPS
6.20
Div Yield, %
2.15%
Shrs. gr., 5y
1.30%
Rev. gr., 5y
2.59%
Revenues
15.43b
+5.04%
2,114,029,1772,690,752,3323,402,820,4853,730,499,2413,786,870,3524,475,508,1974,536,913,8504,950,400,0005,334,800,0005,458,600,0008,120,856,5739,166,717,72110,131,642,14811,899,410,47913,575,278,03213,761,477,64114,469,426,37119,585,285,15714,690,000,00015,430,000,000
Net income
3.00b
+13.63%
87,084,638457,420,695671,445,929924,824,870894,829,3881,005,280,7641,005,587,7351,216,300,0001,307,000,0001,379,000,0001,707,310,6361,337,400,0001,728,900,0002,682,922,1123,136,313,6163,183,882,5363,109,111,2863,336,069,5222,642,000,0003,002,000,000
CFO
3.56b
+26.62%
522,164,000480,840,000715,336,0001,024,824,0001,168,492,0001,018,119,0001,160,000,0001,414,231,8051,444,479,8301,775,520,8331,619,636,4421,652,982,0642,454,829,8852,299,367,8643,711,814,1124,855,454,3823,624,837,3793,866,807,8552,812,389,2323,561,000,000
Dividend
Sep 10, 20240.725 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
URL
https://www.csl.com/
IPO date
Jun 08, 1994
Employees
32,065
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT